Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.

about

New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?

P2860

Q26765488-5C56F001-D3CE-49FA-91B4-1CC134770C16

P2860

Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.

Item

http://www.wikidata.org/entity/Q38015757

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Which antithrombin for whom? I ...... rom novel antithrombin agents.

@en

type

Item

label

Which antithrombin for whom? I ...... rom novel antithrombin agents.

@en

prefLabel

Which antithrombin for whom? I ...... rom novel antithrombin agents.

@en

P1476

Which antithrombin for whom? I ...... rom novel antithrombin agents.

@en

P2093

David A Burke

http://www.w3.org/2001/XMLSchema#string

Duane S Pinto

http://www.w3.org/2001/XMLSchema#string

Haider J Warraich

http://www.w3.org/2001/XMLSchema#string

P2860

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

Bivalirudin for patients with acute coronary syndromes

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

Bivalirudin during primary PCI in acute myocardial infarction

Thrombin signalling and protease-activated receptors

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Validation of the Mayo clinic risk score for in-hospital mortality after percutaneous coronary interventions using the national cardiovascular data registry.

Guidelines on myocardial revascularization.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Rivaroxaban in patients with a recent acute coronary syndrome.

P2888

s11886-012-0286-6

P304

493-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-012-0286-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027369492

http://www.w3.org/2001/XMLSchema#string

P698

22661270

http://www.w3.org/2001/XMLSchema#string

Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.

about

P2860

P2860

Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698